Incyclix Bio

Durham, United States

Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.

Apr 2026

Series B

Biotechnology Health Care Pharmaceutical Therapeutics

Top Investors

RA Capital ManagementHatteras Venture PartnersEli Lilly & Company FoundationCape Fear BioCapitalBoxer Capital

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Incyclix Bio

Who are Incyclix Bio's investors?

Incyclix Bio's investors include RA Capital Management, Hatteras Venture Partners, Eli Lilly & Company Foundation, Cape Fear BioCapital, Boxer Capital.

Where is Incyclix Bio headquartered?

Incyclix Bio is headquartered in Durham, United States.

What does Incyclix Bio do?

Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.

What stage is Incyclix Bio at?

Incyclix Bio is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated April 8, 2026.

MLA

"Incyclix Bio — Funding & Investors." VCBacked, April 8, 2026, https://www.vcbacked.co/company/incyclix-bio. Accessed June 3, 2026.

APA

VCBacked. (2026). Incyclix Bio — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/incyclix-bio

Wikipedia (cite web)

{{cite web |title=Incyclix Bio — Funding & Investors |url=https://www.vcbacked.co/company/incyclix-bio |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated April 8, 2026.

Similar Companies in Biotechnology